Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
54.08 USD | +1.10% | +1.39% | -26.90% |
May. 23 | U.S. FDA advisers back approval for Guardant's cancer test | RE |
May. 21 | Exact Sciences Says Court Allows Patent Lawsuit Against Geneoscopy to Proceed | MT |
Financials (USD)
Sales 2024 * | 2.83B | Sales 2025 * | 3.22B | Capitalization | 9.98B |
---|---|---|---|---|---|
Net income 2024 * | -196M | Net income 2025 * | -25M | EV / Sales 2024 * | 4.09 x |
Net Debt 2024 * | 1.59B | Net Debt 2025 * | 1.18B | EV / Sales 2025 * | 3.47 x |
P/E ratio 2024 * |
-51.6
x | P/E ratio 2025 * |
-551
x | Employees | 6,550 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.02% |
Latest transcript on Exact Sciences Corporation
1 day | +1.10% | ||
1 week | +1.39% | ||
Current month | -8.88% | ||
1 month | -13.35% | ||
3 months | -9.09% | ||
6 months | -17.28% | ||
Current year | -26.90% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Conroy
CEO | Chief Executive Officer | 58 | 09-03-17 |
Paul Limburg
CTO | Chief Tech/Sci/R&D Officer | - | 18-03-05 |
Jorge Garces
CTO | Chief Tech/Sci/R&D Officer | 52 | 21-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
D. Coward
BRD | Director/Board Member | 59 | 14-12-31 |
Kevin Conroy
CEO | Chief Executive Officer | 58 | 09-03-17 |
Freda Lewis-Hall
BRD | Director/Board Member | 69 | 20-04-21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.80% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 54.08 | +1.10% | 5,807,241 |
24-05-22 | 53.49 | -0.06% | 2,612,451 |
24-05-21 | 53.52 | +4.94% | 3,641,687 |
24-05-20 | 51 | +1.23% | 5,629,326 |
24-05-17 | 50.38 | -3.02% | 2,453,347 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.90% | 9.87B | |
-16.78% | 2.75B | |
-17.50% | 2.13B | |
-24.25% | 1.65B | |
+64.58% | 1.47B | |
+31.92% | 811M | |
-5.02% | 733M | |
-29.59% | 510M | |
+0.20% | 300M | |
-28.40% | 166M |
- Stock Market
- Equities
- EXAS Stock